针对抗癌疗法,以结构为导向的识别以线素激活蛋白激酶-1 抑制剂为抗癌疗法
Md Nayab Sulaimani1, Shazia Ahmed2, Farah Anjum3
1Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
PloS one
|January 24, 2025
概括
研究人员确定了三种天然化合物作为线素激活蛋白激酶1 (MAPK1) 的潜在抑制剂. 这些化合物通过向癌症转移中的MAPK1信号来开发新的癌症治疗方法,显示出有前途.
科学领域:
- 生物化学和分子生物学
- 药理学和药物发现
- 计算化学计算化学
背景情况:
- 线素激活蛋白激酶1 (MAPK1) 是MAP激酶信号通路中的关键酶,调节细胞繁殖和生存等关键细胞功能.
- 该MAPK途径与癌症的进展和转移有关,使MAPK1成为一个重要的治疗点.
- 针对MAPK通路的现有化疗药物强调了对新型,特定MAPK1抑制剂的需求.
研究的目的:
- 通过结构引导虚拟选来识别可以抑制MAPK1活动的新型自然化合物.
- 通过向癌症转移来评估这些化合物作为抗癌疗法的潜力.
- 探索潜在的MAPK1抑制剂的结合相互作用和药理动力学特性.
主要方法:
- 大型自然化合物库 (ZINC数据库) 的结构引导虚拟选.
- 使用Lipinski的五项规则 (RO5) 进行初始过,然后进行分子对接,以评估MAPK1.1的结合亲和力和特异性.
- 深度分析包括PAINS过,ADMET预测,PASS分析,分子动力学 (MD) 模拟和结合相互作用分析.
主要成果:
- 三种天然化合物 (ZINC0209285,ZINC02130647,ZINC02133691) 被确定为潜在的MAPK1抑制剂.
- 这些化合物对MAPK1激酶域表现出有利的结合亲和力和特异性.
- 分子动力学模拟证实了已识别的化合物与关键MAPK1残留物的稳定相互作用.
结论:
- 已识别的天然化合物代表了作为抗癌剂进一步开发的有希望的候选者.
- 通过这些新型抑制剂向MAPK1,可以提供一种控制癌症转移的策略.
- 需要进一步的临床前和临床研究来验证这些化合物的治疗潜力.
相关概念视频
MAPK Signaling Cascades
5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


